Immunovant Inc (IMVT)

Sector:
FINANCE
Industry:
GENERAL FINANCE
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Peter Salzmann
Employees:
120
320 WEST 37TH STREET, NEW YORK, NY 10018
917-580-3099

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

Data derived from most recent annual or quarterly report
Market Cap 2.018 Billion Shares Outstanding129.182 Million Avg 30-day Volume 886.626 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.49
Price to Revenue0.0 Debt to Equity0.0 EBITDA-156.688 Million
Price to Book Value1.2863 Operating Margin0.0 Enterprise Value110.516 Million
Current Ratio11.521 EPS Growth0 Quick Ratio11.367
1 Yr BETA 1.1324 52-week High/Low 20.24 / 3.15 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score7.0491 Free Cash Flow to Firm 0
Earnings Report2023-06-07
View SEC Filings from IMVT instead.

View recent insider trading info

Immunovant Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IMVT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMVT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-03 by MACIAS WILLIAM L.
  • 4: filed on 2023-01-27 by LEVINE MARK S.
  • 4: filed on 2023-01-13 by SALZMANN PETER
  • 4: filed on 2023-01-13 by BUTCHKO JULIA G.
  • 4: filed on 2023-01-13 by BARNETT EVA RENEE
  • 4: filed on 2023-01-13 by MACIAS WILLIAM L.
  • 4: filed on 2022-10-25 by MACIAS WILLIAM L.
  • 4: filed on 2022-10-17 by BUTCHKO JULIA G.
  • 4: filed on 2022-10-17 by SALZMANN PETER
  • 4: filed on 2022-10-13 by BARNETT EVA RENEE

    • Events (8k)

  • 8-K: filed on 2023-02-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-28:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-07:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-19:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    10.7 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MACIAS WILLIAM L. CHIEF MEDICAL OFFICER

    • Officer
    		 262,996 2023-02-02 6

    LEVINE MARK S. CHIEF LEGAL OFFICER

    • Officer
    		 245,660 2023-01-26 2

    BUTCHKO JULIA G. CHIEF DEV. & TECH. OFFICER

    • Officer
    		 331,419 2023-01-11 9

    SALZMANN PETER CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 993,932 2023-01-11 9

    BARNETT EVA RENEE CHIEF FINANCIAL OFFICER

    • Officer
    		 268,347 2023-01-11 3

    ROIVANT SCIENCES LTD.

    • 10% Owner
    		 73,805,331 2022-10-06 1

    PANDE ATUL

    • Director
    		 102,985 2022-09-30 2

    TORTI FRANK

    • Director
    		 393,358 2022-09-29 2

    MIGAUSKY GEORGE V

    • Director
    		 109,985 2022-08-17 1

    FROMKIN ANDREW J.

    • Director
    		 88,485 2022-08-17 1

    HUGHES DOUGLAS J.

    • Director
    		 101,232 2022-08-17 1

    JAIN RITA CHIEF MEDICAL OFFICER

    • Officer
    		 129,365 2021-03-19 0

    YANCHIK CONNEALY PAMELA CHIEF FINANCIAL OFFICER

    • Officer
    		 46,200 2021-03-19 0

    ELLIOTT MICHAEL JAMES CHIEF SCIENTIFIC OFFICER

    • Officer
    		 97,600 2021-03-19 0

    WONG RODERICK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 902,498 2019-12-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MACIAS WILLIAM L. - Officer CHIEF MEDICAL OFFICER

    		2023-02-03 07:24:19 -0500 2023-02-02 S 537 $18.24 d 262,996 direct 3.7183 3.831 -5.9155 7.0423 3 -13.9155 29

    LEVINE MARK S. - Officer CHIEF LEGAL OFFICER

    		2023-01-27 07:20:19 -0500 2023-01-26 S 10,156 $18.51 d 245,660 direct -2.6524 0.1693 -10.8352 7.2235 8 -12.246 30

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    IMMUNOVANT INC IMVT 2023-03-24 22:15:03 UTC 4.5256 0.2944 600000
    IMMUNOVANT INC IMVT 2023-03-24 21:45:03 UTC 4.5256 0.2944 600000
    IMMUNOVANT INC IMVT 2023-03-24 21:15:03 UTC 4.5256 0.2944 600000
    IMMUNOVANT INC IMVT 2023-03-24 20:45:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 20:15:04 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 19:45:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 19:15:04 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 18:45:04 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 18:15:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 17:45:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 17:15:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 16:45:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 16:15:03 UTC 4.4446 0.3754 550000
    IMMUNOVANT INC IMVT 2023-03-24 15:45:03 UTC 4.4446 0.3754 550000
    IMMUNOVANT INC IMVT 2023-03-24 15:15:03 UTC 4.4446 0.3754 600000
    IMMUNOVANT INC IMVT 2023-03-24 14:45:03 UTC 4.4446 0.3754 650000
    IMMUNOVANT INC IMVT 2023-03-24 14:15:03 UTC 4.4446 0.3754 550000
    IMMUNOVANT INC IMVT 2023-03-24 13:45:03 UTC 4.2659 0.3041 550000
    IMMUNOVANT INC IMVT 2023-03-24 13:15:04 UTC 4.2659 0.3041 550000
    IMMUNOVANT INC IMVT 2023-03-24 12:45:03 UTC 4.2659 0.3041 600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund IMVT -4656.0 shares, $-52147.2 2022-10-31 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund IMVT -1236.0 shares, $-21939.0 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments